GlassScriptPhysician profile
Ericka A Flipping
NPI 1225344534
$6,338.00
in general payments reported to CMS, 2019-2025
30 companies · $2,638 in 2025
The $2,638 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,240 · 2022: $799 · 2023: $611 · 2024: $1,051 · 2025: $2,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,216 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,215.66 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,528.10 | 2021-2025 | |
| Janssen Biotech, INC. | $1,050.47 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $677.03 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.67 | 2021-2025 | Xifaxan |
| Gilead Sciences, INC. | $239.41 | 2021-2025 | |
| Ardelyx, INC. | $227.87 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $214.99 | 2021-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $210.46 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $190.51 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $177.96 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $170.24 | 2021-2024 | Dificid |
| Pfizer INC. | $168.55 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $146.90 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $143.15 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $131.36 | 2021-2024 | Ocaliva |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $116.63 | 2021-2023 | Rebyota |
| Genzyme Corporation | $115.78 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $110.81 | 2024-2025 | Zenpep |
| Celgene Corporation | $95.48 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $58.54 | 2022-2024 | Givlaari |
| Lilly USA, LLC | $45.94 | 2025 | Omvoh |
| Tempus Ai, INC | $28.64 | 2025 | Xt Cdx |
| Alcresta Therapeutics, INC. | $26.13 | 2024 | Relizorb |
| Organon LLC | $24.89 | 2024 | |
| Novo Nordisk INC | $20.37 | 2025 | Wegovy |
| Curium US LLC | $19.09 | 2024 | Detectnet |
| Sandoz INC. | $15.02 | 2025 | |
| Exact Sciences Corporation | $14.64 | 2023 | Cologuard Collection Kit |
| Mallinckrodt Hospital Products INC. | $14.37 | 2025 | Terlivaz |
| Redhill Biopharma INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ericka Flipping listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.